Biologics or biopharmaceuticals have offered new and exciting options for the treatment of diseases previously considered incurable and are becoming one of the most promising categories of drugs in the 21<sup>st</sup> century. Given the intense and growing interest these drugs are receiving, CAS, a division of American Chemical Society, has conducted, in collaboration of National Science Library, the Chinese Academy of Science, a series of scientific analyses in order to help organizations stay abreast of the rapid development in this area. The big data analyses were based on 30 years’ worth of published data on four major classes of biologics: antibodies, fusion protein, gene and cell therapy, and vaccines. About 250,000 substances and 500,000 published documents were extracted from CAS’s curated substance collection and document database, respectively. Comprehensive analyses of global R&D trends were conducted from various perspectives that covered organization sources, patent flow, molecular types, targets, disease indications, among others. Our analyses have revealed interesting findings and also identified both opportunities for rapid and new successes in biologics development and potential challenges.

Trends in biologics research and development: Analytic studies based on CAS-curated data

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.